ETHYLENEDICYSTEINE (EC)-DRUG CONJUGATES, COMPOSITIONS AND METHODS FOR TISSUE SPECIFIC DISEASE IMAGING

• Main Authors: YU, DONG-FANG, BRYANT, JERRY, L., JR, YANG, DAVID, J, OH, CHANG-SOK
• Format: Patent
• Language: English; French
• Published: 27.05.2004
• Edition: 7
• Subjects: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM; BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROMTHE BODY; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

The invention provides, in a general sense, a new labeling strategy employing compounds that are are N2S2 chelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a disease receptor targeting ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD31, monoclonal antibody CD40, capecitabine, COX-2, deoxycytidine, fullerene, herceptin, human serum albumin, lactose, leuteinizing hormone, pyridoxal, quinazoline, thalidomide, transferrin, or trimethyl lysine. The present invention also pertains to kits employing the compounds of interest, and methods of assessing the pharmacology of an agent of interest using the present compounds. L'invention concerne, de façon générale, une nouvelle stratégie de marquage à l'aide de composés constitués de N2S2-chélates conjugués à un ligand de ciblage, ce ligand de ciblage pouvant être un composé de ciblage de cycles cellulaires de maladies, un ligand de ciblage de l'angiogenèse tumorale, un ligand de ciblage de l'apoptose tumorale, un ligand de ciblage de récepteurs associés à des maladies, l'amifostine, l'angiostatine, l'anticorps monoclonal C225, l'anticorps monoclonal CD31, l'anticorps monoclonal CD40, la capécitabine, la COX-2, la désoxycytidine, le fullerène, l'herceptine, l'albumine sérique humaine, le lactose, l'hormone lutéinisante, le pyridoxal, la quinazoline, la thalidomide, la transferrine ou la triméthyl-lysine. Ladite invention concerne également des trousses utilisant les composés d'intérêt ainsi que des méthodes d'évaluation des propriétés pharmacologiques d'un agent d'intérêt à l'aide des présents composés.